MDT to Evaluate the Survival Benefit of Patients With Advanced Gastric / Colorectal Cancer

• Conditions: Multi-disciplinary Treatment
• Interventions: Procedure: Multi-disciplinary Treatment

• Registration Number: NCT03400657
• Lead Sponsor: Peking University

Brief Summary

This is a prospective, multicenter, non-interventional, controlled clinical study. Evaluate MDT performance and benefit analysis in patients with advanced gastric or colorectal cancer after MDT discussion under real medical practice.

Detailed Description

Not available

Study Timeline

• Study Start: 2017-11-01
• Status Verified: 2018-01
• Study First Submitted: 2018-01-02
• Study First Submitted QC: 2018-01-09
• Last Update Submitted: 2018-01-09
• Study First Posted: 2018-01-17
• Last Update Posted: 2018-01-17
• Primary Completion: 2020-01
• Study Completion: 2020-06

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 484

Inclusion Criteria

1. Histopathological diagnosis of recurrent / metastatic gastric or colorectal cancer.
2. Participate in formal MDT discussions at the Research Center.
3. MDT decision-making at least two subjects involved in treatment.
4. Patient informed consent and signed written consent.

Exclusion Criteria

1. Early or locally advanced gastric cancer or colorectal cancer.
2. Accept informal MDT discussions.
3. MDT decisions recommend only a single subject for treatment of patients.
4. MDT decisions recommend only palliative patients.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
fully implemented to the MDT decision	Multi-disciplinary Treatment	group of patients fully implemented to the MDT decision
not completly implemented to the MDT-decision	Multi-disciplinary Treatment	group of patients not completly implemented to the MDT decision
not implemented to the MDT decision	Multi-disciplinary Treatment	group of patients not implemented to the MDT decision

Primary Outcome Measures

Name	Time	Method
overall survival	From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months	From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months

Secondary Outcome Measures

Name	Time	Method
Differences in overall survival after performing MDT at center	1 years	Differences in overall survival after performing MDT at center

Trial Locations

Locations (1)

Beijing Cancer Hospital; 🇨🇳 Beijing, Beijing, China